论文部分内容阅读
目的交叉对比分析瑞格列奈和格列齐特的动态血糖图谱,观察比较血糖波动系数、低血糖发生率和餐后血糖峰值。方法 T2DM患者52例,分别应用瑞格列奈或格列齐特,常规检查血糖。采用交叉设计,应用瑞格列奈组患者改用格列齐特,应用格列齐特组患者改用瑞格列奈,改用前后分别予动态血糖监测72 h。原有饮食运动及联用口服药物不变。以用瑞格列奈为研究组,用格列齐特为对照组,对比分析两组血糖波动系数、低血糖发生率和餐后血糖峰值。结果经2周洗脱期、8周剂量调整期、2周剂量维持期、3 d监测期后的结果显示:应用瑞格列奈比应用格列齐特血糖控制更平稳,动态血糖图谱表现为血糖波动系数小,低血糖次数少,低血糖时间比少(P<0.01),餐后血糖峰值低(P<0.05)。结论本研究条件下,应用瑞格列奈比应用格列齐特似可减少血糖漂移幅度。
Objective To compare and analyze the dynamic blood glucose profiles of repaglinide and gliclazide, and to compare and contrast the blood glucose fluctuation coefficient, the incidence of hypoglycemia and the postprandial blood glucose peak. Methods Twenty-two patients with T2DM were treated with repaglinide or gliclazide, and blood glucose was measured routinely. The crossover design was used to apply gliclazide instead of repaglinide. The patients in the application of gliclazide were switched to repaglinide, and the blood glucose was monitored 72 h before and after switching to repaglinide. The original diet exercise and oral medication unchanged. To use repaglinide as the research group, with gliclazide as control group, comparative analysis of two groups of blood glucose fluctuation coefficient, the incidence of hypoglycemia and postprandial blood glucose peak. Results After 2 weeks of elution, 8 weeks of dose adjustment, 2 weeks of maintenance dose, 3 days after the monitoring period results show that: the application of repaglinide than the application of gliclazide glycemic control more stable dynamic glucose profile Small fluctuations in blood glucose, low frequency of hypoglycemia, hypoglycemia time less (P <0.01), postprandial peak blood glucose (P <0.05). Conclusion Under the condition of this study, the application of repaglinide to glycyrrhizin can reduce the extent of glycemic excursion.